arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Instil Bio, Inc.

TIL

$7.39 ▲ +0.15 (+2.14%) at close

7 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Instil Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $49.3M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -69.0% ↘

FCF / Share $-5.49 ↗

Trailing P/E —

Price / Book 0.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-71.37M

↑ +3.7% —

FCF / Share Free cash flow per share

$-5.49

↑ +35.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	6.1% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	52.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	30.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-16.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	37.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	3.7% Caution ↓ Caution Declining Year-over-year change in net income	52.5% Excellent ↑ Excellent Improving Year-over-year change in net income	30.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-42.3% Weak Weak Year-over-year change in net income	-315.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	35.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	45.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	61.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-20.4% Weak Weak Year-over-year change in free cash flow	66.2% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.9% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.51x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	2.13x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-69.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-70.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-61.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-28.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	85.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-38.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-48.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-62.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-518%)	-43.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-392%)	-69.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-561%)	-61.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-509%)	-28.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-288%)	95.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+535%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	-15.60x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-9.20x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-30.56x Weak Weak Operating income divided by interest expense Optimal: > 5x	-120.26x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-6.64M	$-8.80M	$-9.20M	$-43.72M	$-37.59M	$-241.71M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	—	—	—	$0.17	—
Basic EPS, GAAP (USD)	$-10.70	$-11.39	$-24.00	$-34.40	$-29.60	$-47.20	—
Free Cash Flow per Share (USD)	$-5.49	$-8.56	$-15.79	$-40.88	$-33.96	$-100.55	—
Book Value per Share (USD)	$16.79	$25.96	$34.72	$55.91	$86.06	$-38.46	—
Tangible Book Value per Share (USD)	$16.79	$25.96	$34.72	$55.91	$85.17	$-44.02	—
Basic Weighted Avg Shares (shares)	6.67M	6.51M	6.50M	6.48M	5.30M	799,890	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$186.59M	$116.57M	$150.20M	$236.59M	$422.66M	$232.86M	—
Total Equity (USD)	$113.87M	$169.44M	$225.83M	$363.61M	$555.20M	$-39.60M	$-6.89M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	$138.00K	—
Depreciation Expense (USD)	$534.00K	$3.61M	$4.76M	$5.99M	$2.75M	$256.00K	—
Net Income, GAAP (USD)	$-71.37M	$-74.14M	$-156.09M	$-223.18M	$-156.79M	$-37.74M	—
Operating Cash Flow (USD)	$-36.62M	$-55.70M	$-82.03M	$-180.16M	$-122.14M	$-29.62M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Instil Bio, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TIL with peers